Virpax Pharmaceuticals Inc (NASDAQ:VRPX) expanded its exclusive license agreement for AnQlar with Nanomerics Ltd, providing Virpax with the worldwide rights for development and commercialization.
- Virpax has completed in-vitro, ex-vivo (human mucosal cells), and in-vivo (rats) studies on AnQlar, which demonstrated that AnQlar inhibited viral replication of SARS-CoV-2 and influenza in animals at ranges higher than those encountered in human nasal passages.
- No adverse effects were observed during the studies.
- Animal studies also demonstrated decreased levels of the virus in animal brain tissue.
- Virpax anticipates completing Investigational New Drug (IND)-enabling studies by Q4 FY22 and pursuing a nonprescription drug approval pathway.
- AnQlar (GCPQ) is a positively-charged chitosan derivative that binds electrostatically to negatively charged viruses such as SARS-CoV-2 and influenza.
- AnQlar can prevent the binding of coronavirus to the cell surface ACE-2 receptor that mediates viral infection.
- Price Action: VRPX shares are up 5.79% at $2.01 during the market session on the last check Tuesday.
